Skip to main content

Novel Rx

      Treatment of RA-ILD patients with ABA at any time of the course in the ILD seems to prevent interstitial lung progressio
      1 year 1 month ago
      Treatment of RA-ILD patients with ABA at any time of the course in the ILD seems to prevent interstitial lung progression. The evolution of FVC and DLCO for 48 months remained stable with ABA therapy. Serrano-Combarro A, Abst#2173 #ACR23 @RheumNow https://t.co/QE61wzKWXi https://t.co/xd3wvMXUlA
      Continued interest on CAR-T cells in systemic sclerosis!

      6 mo f/up data on 3 pts who received CAR-T cell treatment - st
      1 year 1 month ago
      Continued interest on CAR-T cells in systemic sclerosis! 6 mo f/up data on 3 pts who received CAR-T cell treatment - stable dz overall Skin findings improved in all 3 pts Previous finger ulcerations resolved Lung function stable in 2 pts, improved in 1 @RheumNow #ACR23 Abs#2598
      #ACR23 Abs 2598 show data on 1st 3 CD19 CAR-T treated SSc pts. Tx well tolerated and dz stabilized off tx x 6 months. Pr
      1 year 1 month ago
      #ACR23 Abs 2598 show data on 1st 3 CD19 CAR-T treated SSc pts. Tx well tolerated and dz stabilized off tx x 6 months. Promising, but more data needed for further evaluation. https://t.co/RAKhT6Eygn @rheumnow
      Interesting late breaker!
      Telitacicept - recombinant fusion protein targeting BLyS and APRIL for treatment of RA
      Phase 3
      1 year 1 month ago
      Interesting late breaker! Telitacicept - recombinant fusion protein targeting BLyS and APRIL for treatment of RA Phase 3 study - at wk 24, reached ACR20, ACR50, DAS28-ESR, no radiographic progression No difference in safety profile compared to placebo @RheumNow #ACR23 #ACRBest https://t.co/bxWPagGixt
      #ACR23 Abstr#2576 Promising therapy in Dermatomyositis. Phase 2 RCT showed rapid improvement in skin, muscle & patie
      1 year 1 month ago
      #ACR23 Abstr#2576 Promising therapy in Dermatomyositis. Phase 2 RCT showed rapid improvement in skin, muscle & patient reported outcomes as fast as Week 4 in PF-06823859 (anti-IFN-B) vs PBO. Could be useful to treat in either skin or muscle predominant patients @RheumNow #ACRBest https://t.co/Rj1k1z0Tsz
      Window of opportunity for abatacept in RA-ILD. Early treated patients (<6 months vs >2 years) appear to do better
      1 year 1 month ago
      Window of opportunity for abatacept in RA-ILD. Early treated patients (<6 months vs >2 years) appear to do better in terms of FVC. Abstr#2173 #ACR23 @RheumNow https://t.co/14IsA1KbAk https://t.co/ZbZEwzaOu0
      L20 @ #ACR23

      New therapy on the horizon for RA pts that failed MTX?

      ⭐️Telitacicept = recombinant fusion protein ta
      L20 @ #ACR23 New therapy on the horizon for RA pts that failed MTX? ⭐️Telitacicept = recombinant fusion protein targeting & neutralizing BLyS & APRIL ➡️ placebo-controlled, phase III trial, 24w 👉at wk 24, PBO pts switched to drug arm for 24 more wks ➡️ 479 pts w/… https://t.co/94MyC8sdaG https://t.co/x3MUmFJPK6
      ×